Alentis Therapeutics Gains $181.4 Million Funding to Advance Anti-Claudin-1 ADCs in Solid Tumors

Retrieved on: 2024-11-19 16:41:37

Tags for this article:

Click the tags to see associated articles and topics

Alentis Therapeutics Gains $181.4 Million Funding to Advance Anti-Claudin-1 ADCs in Solid Tumors. View article details on hiswai:

Summary

The article discusses Alentis Therapeutics' $181.4 million funding round to advance CLDN1-targeted antibody-drug conjugates (ADCs) against solid tumors. This aligns with the biopharma focus on biotechnology innovations and OrbiMed's backing.

Article found on: www.biopharminternational.com

View Original Article